

## Electronic Supplementary Information (ESI)

# Co-crystal Formation vs. Boron Coordination: Fluorination in Azopyridines Regulates Supramolecular Competition

Jesus Daniel Loya,<sup>a,†</sup> Sidhaesh A. Agarwal,<sup>a,†</sup> Nicholas Lutz,<sup>a</sup> Eric W. Reinheimer,<sup>b</sup> and  
Gonzalo Campillo-Alvarado<sup>a,\*</sup>

<sup>a</sup>Department of Chemistry, Reed College, Portland, OR 97202, USA.

<sup>b</sup>Rigaku Oxford Diffraction, The Woodlands, Texas, 77381, USA

<sup>†</sup>These authors contributed equally.

\*e-mail: gcampillo@reed.edu

### Table of Contents:

- S1) Experimental information
- S2) Single-crystal X-ray data
- S3) Powder X-ray data and phase analysis
- S4) NMR Spectra
- S5) Hirshfeld analysis

## S1. Experimental information

### Materials:

3-Fluoro-4-aminopyridine, 3,5-difluoro-4-aminopyridine, 2,3,5,6-tetrafluoro-4-aminopyridine, 4,4'-azopyridine, phenylboronic acid were obtained from AmBeed. Catechol was purchased from TCI. Acetonitrile, dichloromethane (DCM), deuterated water (D<sub>2</sub>O), MgSO<sub>4</sub>, and sodium hypochlorite solution were obtained from Sigma-Aldrich. All reagents and solvent were used as received.

### General synthetic method of azopyridines:

The synthetic procedure was adapted from the literature.<sup>1</sup> A fluorinated aminopyridine (500 mg) was dissolved in D<sub>2</sub>O (100 mL) to which 40 mL cold sodium hypochlorite solution was added dropwise with vigorous stirring at 0 °C affording a deep yellow solution. The aqueous layer was extracted with DCM (3 x 100 mL). The resulting solution was dried over MgSO<sub>4</sub> and filtered. The filtrate was concentrated to produce crystalline solids.

**Synthesis of diF-azop:** 3-fluoro-4-aminopyridine was reacted using the general synthetic method of azopyridines to afford **diF-azop** as a red solid. Recrystallization in acetonitrile afforded single crystals as black planks (210.3 mg, 42.8 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.80 (d, *J* = 2.0 Hz, 2H), 8.61 (d, *J* = 5.0 Hz, 2H), 7.59 (t, *J* = 5.7 Hz, 2H) ppm; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ -138 (s, 2F) ppm; <sup>19</sup>F NMR spectrum showed traces of the *cis* isomer.

**Synthesis of tetraF-azop:** 3,5-difluoro-4-aminopyridine was reacted using the general synthetic method of azopyridines to afford **tetraF-azop** as a red solid. Recrystallization in acetonitrile afforded single crystals in the form of black blocks (279.80 mg, 56.8 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.54 (m, 4H) ppm; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ -137 (s, 4F) ppm. <sup>19</sup>F NMR showed the presence of *cis:trans* isomers (ratio: 17:83).

**Synthesis of perF-azop:** 2,3,5,6-tetrafluoro-4-aminopyridine was reacted using an adapted procedure using 500 mL of D<sub>2</sub>O rather than 100 mL. **perF-azop** was isolated as a red solid. Single crystals in the form of red irregular planks were obtained after rotary evaporation (140.00 mg, 28.3%). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ -87 (m, 2F), -150 (m, 2F) ppm. Note: <sup>19</sup>F NMR showed the presence of *cis:trans* isomers (ratio: 17:83).

### General synthetic method of adducts

Azopyridine (**azop**, **diF-azop**, **tetraF-azop**) (0.015 mmol) was combined with phenylboronic acid (**PhBA**, 0.30 mmol) and catechol (**cat**, 0.30 mmol) in acetonitrile (3 mL). The solutions were gently heated until the solids fully dissolved. Single crystals of the adducts (**PhBE**)·(**diF-azop**), (**PhBE**)·(**tetraF-azop**) were observed after three days of

slow evaporation. For the case of **(PhBE)·(azop)**, the vial containing the solution was sealed, and single crystals were observed after three days under 4 °C.

Synthesis of **(PhBE)·(perF-azop)**: **perF-azop** (0.015 mmol) was combined with **PhBA** (0.15 mmol) and **cat**, (0.15 mmol) in acetonitrile (3 mL). The solution was gently heated until the solids fully dissolved. Single crystals of **(PhBE)·(perF-azop)** were observed after three days of slow evaporation. Initial attempts using **perF-azop** (0.015 mmol) with **PhBA** (0.30 mmol) and **cat** (0.30 mmol) afforded crystals of **(PhBE)·(perF-azop)** with the presence of crystal of pure **PhBE**.

We note adducts **(PhBE)·(azop)**, **(PhBE)·(diF-azop)**, and **(PhBE)·(tetraF-azop)** hydrolyze when dissolved in DMSO-*d*<sub>6</sub> into the corresponding azopyridine, catechol and phenylboronic acid

All the synthesized solids were protected from light in vials wrapped with aluminum foil. X-ray diffraction experiments were performed in an environment with minimum light.

#### **Instruments and methods:**

<sup>1</sup>H and <sup>19</sup>F NMR spectra were recorded on a Bruker Ascend Evo 400 MHz spectrometer with chloroform-*d*, DMSO-*d*<sub>6</sub> and TMS as internal standards. <sup>19</sup>F NMR experiments were decoupled. NMR data was processed with Mnova suite. Single crystal X-ray diffraction (SCXRD) data was collected on a Rigaku XtaLAB Mini II diffractometer with a CCD area detector ( $\lambda\text{MoK}\alpha = 0.71073 \text{ \AA}$ , monochromator: graphite). Experiments were conducted at 100 K with a range of  $2\theta = 3\text{-}62^\circ$ . The collected data was refined with CrysAlisPro through standard data reduction and background corrections (multi-scan was used for all samples). Crystals were mounted in Paratone oil on a Mitegen magnetic mount. Structure solution and refinement were performed using SHELXT<sup>2</sup> and SHELXL,<sup>3</sup> respectively within the Olex2<sup>4</sup> graphical user interface. All the hydrogen atoms were added in geometrically calculated positions using a riding model with appropriate AFIX instructions.

#### **Computational methods:**

Single point energy calculations at ground state in the gas phase were performed using the Spartan '20 graphical user interface using geometrical coordinates obtained from single crystal X-ray diffraction data. Density Functional Theory (DFT) was used with the  $\omega\text{B97X-D}$  exchange-correlation functional and correlated corrected basis set cc-pVTZ.<sup>5</sup> Electrostatic potential maps were computed and mapped using the isodensity surface 0.002 e/au<sup>3</sup> with medium resolution.

## S2. Single-crystal X-ray data

Table S1. Crystallographic parameters for (PhBE)·(azop)

<b>Compound name</b>	(PhBE)·(azop)
<b>Empirical formula</b>	C <sub>34</sub> H <sub>26</sub> B <sub>2</sub> N <sub>4</sub> O <sub>4</sub>
<b>Formula weight</b>	576.21
<b>Temperature/K</b>	99.9(6)
<b>Crystal system</b>	monoclinic
<b>Space group</b>	<i>P</i> 2 <sub>1</sub> / <i>c</i>
<b>a/Å</b>	6.8631(2)
<b>b/Å</b>	13.1490(3)
<b>c/Å</b>	15.7054(4)
<b>α/°</b>	90
<b>β/°</b>	99.615(3)
<b>γ/°</b>	90
<b>Volume/Å<sup>3</sup></b>	1397.39(6)
<b>Z</b>	2
<b>ρ<sub>calc</sub>/g/cm<sup>3</sup></b>	1.369
<b>μ/mm<sup>-1</sup></b>	0.090
<b>F(000)</b>	600.0
<b>Crystal size/mm<sup>3</sup></b>	0.32 × 0.25 × 0.17
<b>Radiation</b>	Mo Kα (λ = 0.71073)
<b>2θ range for data collection/°</b>	4.064 to 61.294
<b>Index ranges</b>	-9 ≤ h ≤ 9, -17 ≤ k ≤ 18, -22 ≤ l ≤ 20
<b>Reflections collected</b>	12564
<b>Independent reflections</b>	4129 [R <sub>int</sub> = 0.0275, R <sub>sigma</sub> = 0.0320]
<b>Data/restraints/parameters</b>	4129/15/222
<b>Goodness-of-fit on F<sup>2</sup></b>	1.039
<b>Final R indexes [I ≥ 2σ (I)]</b>	R <sub>1</sub> = 0.0543, wR <sub>2</sub> = 0.1366
<b>Final R indexes [all data]</b>	R <sub>1</sub> = 0.0669, wR <sub>2</sub> = 0.1442
<b>CCDC deposition number</b>	2347089

**Table S2.** Crystallographic parameters for **(PhBE)·(diF-azop)**

<b>Compound name</b>	<b>(PhBE)·(diF-azop)</b>
<b>Empirical formula</b>	C <sub>34</sub> H <sub>24</sub> B <sub>2</sub> F <sub>2</sub> N <sub>4</sub> O <sub>4</sub>
<b>Formula weight</b>	612.19
<b>Temperature/K</b>	99.9(6)
<b>Crystal system</b>	monoclinic
<b>Space group</b>	<i>P</i> 2 <sub>1</sub> / <i>c</i>
<b>a/Å</b>	6.8710(3)
<b>b/Å</b>	13.0541(6)
<b>c/Å</b>	15.9373(7)
<b>α/°</b>	90
<b>β/°</b>	97.627(4)
<b>γ/°</b>	90
<b>Volume/Å<sup>3</sup></b>	1416.86(11)
<b>Z</b>	2
<b>ρ<sub>calc</sub>/g/cm<sup>3</sup></b>	1.435
<b>μ/mm<sup>-1</sup></b>	0.103
<b>F(000)</b>	632.0
<b>Crystal size/mm<sup>3</sup></b>	0.47 × 0.24 × 0.11
<b>Radiation</b>	Mo Kα (λ = 0.71073)
<b>2θ range for data collection/°</b>	4.048 to 49.996
<b>Index ranges</b>	-8 ≤ h ≤ 8, -15 ≤ k ≤ 15, -14 ≤ l ≤ 18
<b>Reflections collected</b>	9101
<b>Independent reflections</b>	2494 [R <sub>int</sub> = 0.0788, R <sub>sigma</sub> = 0.0636]
<b>Data/restraints/parameters</b>	2494/0/208
<b>Goodness-of-fit on F<sup>2</sup></b>	1.049
<b>Final R indexes [I ≥ 2σ (I)]</b>	R <sub>1</sub> = 0.0508, wR <sub>2</sub> = 0.1356
<b>Final R indexes [all data]</b>	R <sub>1</sub> = 0.0637, wR <sub>2</sub> = 0.1436
<b>CCDC deposition number</b>	2347091

**Table S3.** Crystallographic parameters for **(PhBE)·(tetraF-azop)**

<b>Compound name</b>	<b>(PhBE)·(tetraF-azop)</b>
<b>Empirical formula</b>	C <sub>34</sub> H <sub>22</sub> B <sub>2</sub> F <sub>4</sub> N <sub>4</sub> O <sub>4</sub>
<b>Formula weight</b>	648.17
<b>Temperature/K</b>	100.00(6)
<b>Crystal system</b>	monoclinic
<b>Space group</b>	<i>P</i> 2 <sub>1</sub> / <i>c</i>
<b>a/Å</b>	7.0434(4)
<b>b/Å</b>	12.8068(7)
<b>c/Å</b>	16.0013(9)
<b>α/°</b>	90
<b>β/°</b>	98.123(5)
<b>γ/°</b>	90
<b>Volume/Å<sup>3</sup></b>	1428.89(14)
<b>Z</b>	2
<b>ρ<sub>calc</sub>/g/cm<sup>3</sup></b>	1.507
<b>μ/mm<sup>-1</sup></b>	0.117
<b>F(000)</b>	664.0
<b>Crystal size/mm<sup>3</sup></b>	0.19 × 0.13 × 0.09
<b>Radiation</b>	Mo Kα (λ = 0.71073)
<b>2θ range for data collection/°</b>	4.09 to 49.992
<b>Index ranges</b>	-8 ≤ h ≤ 8, -15 ≤ k ≤ 15, -19 ≤ l ≤ 19
<b>Reflections collected</b>	9008
<b>Independent reflections</b>	2526 [R <sub>int</sub> = 0.0747, R <sub>sigma</sub> = 0.0815]
<b>Data/restraints/parameters</b>	2526/0/217
<b>Goodness-of-fit on F<sup>2</sup></b>	0.978
<b>Final R indexes [I ≥ 2σ (I)]</b>	R <sub>1</sub> = 0.0446, wR <sub>2</sub> = 0.0997
<b>Final R indexes [all data]</b>	R <sub>1</sub> = 0.0755, wR <sub>2</sub> = 0.1104
<b>CDCC deposition number</b>	2347088

**Table S4.** Crystallographic parameters for (PhBE)·(perF-azop)

<b>Compound name</b>	<b>(PhBE)·(perF-azop)</b>
<b>Empirical formula</b>	C <sub>22</sub> H <sub>9</sub> BF <sub>8</sub> N <sub>4</sub> O <sub>2</sub>
<b>Formula weight</b>	524.14
<b>Temperature/K</b>	99.9(5)
<b>Crystal system</b>	triclinic
<b>Space group</b>	<i>P</i> -1
<b>a/Å</b>	6.2144(12)
<b>b/Å</b>	7.2948(13)
<b>c/Å</b>	11.7785(17)
<b>α/°</b>	81.392(13)
<b>β/°</b>	77.890(15)
<b>γ/°</b>	85.140(16)
<b>Volume/Å<sup>3</sup></b>	515.41(16)
<b>Z</b>	1
<b>ρ<sub>calc</sub>/g/cm<sup>3</sup></b>	1.689
<b>μ/mm<sup>-1</sup></b>	0.159
<b>F(000)</b>	262.0
<b>Crystal size/mm<sup>3</sup></b>	0.552 × 0.161 × 0.089
<b>Radiation</b>	Mo Kα (λ = 0.71073)
<b>2θ range for data collection/°</b>	5.656 to 52.744
<b>Index ranges</b>	-7 ≤ h ≤ 7, -9 ≤ k ≤ 9, -14 ≤ l ≤ 14
<b>Reflections collected</b>	6510
<b>Independent reflections</b>	2083 [R <sub>int</sub> = 0.0498, R <sub>sigma</sub> = 0.0590]
<b>Data/restraints/parameters</b>	2083/90/208
<b>Goodness-of-fit on F<sup>2</sup></b>	1.013
<b>Final R indexes [I ≥ 2σ (I)]</b>	R <sub>1</sub> = 0.0544, wR <sub>2</sub> = 0.1403
<b>Final R indexes [all data]</b>	R <sub>1</sub> = 0.0827, wR <sub>2</sub> = 0.1614
<b>CCDC deposition number</b>	2347087

**Table S5.** Crystallographic parameters for **diF-azop**

<b>Compound name</b>	<b>diF-azop</b>
<b>Empirical formula</b>	C <sub>10</sub> H <sub>6</sub> F <sub>2</sub> N <sub>4</sub>
<b>Formula weight</b>	220.19
<b>Temperature/K</b>	99.9(7)
<b>Crystal system</b>	orthorhombic
<b>Space group</b>	<i>Pbca</i>
<b>a/Å</b>	6.6796(6)
<b>b/Å</b>	12.6700(7)
<b>c/Å</b>	22.3037(14)
<b>α/°</b>	90
<b>β/°</b>	90
<b>γ/°</b>	90
<b>Volume/Å<sup>3</sup></b>	1887.6(2)
<b>Z</b>	8
<b>ρ<sub>calc</sub>/cm<sup>3</sup></b>	1.550
<b>μ/mm<sup>-1</sup></b>	0.127
<b>F(000)</b>	896.0
<b>Crystal size/mm<sup>3</sup></b>	0.267 × 0.072 × 0.063
<b>Radiation</b>	Mo Kα (λ = 0.71073)
<b>2θ range for data collection/°</b>	6.432 to 49.984
<b>Index ranges</b>	-7 ≤ h ≤ 7, -14 ≤ k ≤ 13, -26 ≤ l ≤ 26
<b>Reflections collected</b>	13924
<b>Independent reflections</b>	1651 [R <sub>int</sub> = 0.0927, R <sub>sigma</sub> = 0.0674]
<b>Data/restraints/parameters</b>	1651/0/145
<b>Goodness-of-fit on F<sup>2</sup></b>	0.958
<b>Final R indexes [I ≥ 2σ (I)]</b>	R <sub>1</sub> = 0.0568, wR <sub>2</sub> = 0.1419
<b>Final R indexes [all data]</b>	R <sub>1</sub> = 0.0850, wR <sub>2</sub> = 0.1557
<b>CCDC deposition number</b>	2347092




**Table S6.** Crystallographic parameters for **tetraF-azop**

<b>Compound name</b>	<b>tetraF-azop</b>
<b>Empirical formula</b>	C <sub>10</sub> H <sub>4</sub> F <sub>4</sub> N <sub>4</sub>
<b>Formula weight</b>	256.17
<b>Temperature/K</b>	99.9(7)
<b>Crystal system</b>	monoclinic
<b>Space group</b>	<i>P2<sub>1</sub>/c</i>
<b>a/Å</b>	5.0686(6)
<b>b/Å</b>	5.1891(7)
<b>c/Å</b>	18.590(2)
<b>α/°</b>	90
<b>β/°</b>	90.109(12)
<b>γ/°</b>	90
<b>Volume/Å<sup>3</sup></b>	488.96(11)
<b>Z</b>	2
<b>ρ<sub>calc</sub>/g/cm<sup>3</sup></b>	1.740
<b>μ/mm<sup>-1</sup></b>	0.164
<b>F(000)</b>	256.0
<b>Crystal size/mm<sup>3</sup></b>	0.54 × 0.5 × 0.05
<b>Radiation</b>	Mo Kα (λ = 0.71073)
<b>2θ range for data collection/°</b>	4.382 to 49.982
<b>Index ranges</b>	-6 ≤ h ≤ 5, -6 ≤ k ≤ 6, -21 ≤ l ≤ 22
<b>Reflections collected</b>	2309
<b>Independent reflections</b>	848 [R <sub>int</sub> = 0.0390, R <sub>sigma</sub> = 0.0542]
<b>Data/restraints/parameters</b>	848/0/83
<b>Goodness-of-fit on F<sup>2</sup></b>	1.107
<b>Final R indexes [I ≥ 2σ (I)]</b>	R <sub>1</sub> = 0.0478, wR <sub>2</sub> = 0.1287
<b>Final R indexes [all data]</b>	R <sub>1</sub> = 0.0565, wR <sub>2</sub> = 0.1351
<b>CCDC deposition number</b>	2347090


**Table S7.** Crystallographic parameters for **perF-azop**

<b>Compound name</b>	<b>perF-azop</b>
<b>Empirical formula</b>	C <sub>10</sub> F <sub>8</sub> N <sub>4</sub>
<b>Formula weight</b>	328.14
<b>Temperature/K</b>	100.15
<b>Crystal system</b>	monoclinic
<b>Space group</b>	<i>P2<sub>1</sub>/c</i>
<b>a/Å</b>	5.8251(6)
<b>b/Å</b>	15.5339(18)
<b>c/Å</b>	5.9792(8)
<b>α/°</b>	90
<b>β/°</b>	100.851(12)
<b>γ/°</b>	90
<b>Volume/Å<sup>3</sup></b>	531.36(11)
<b>Z</b>	2
<b>ρ<sub>calc</sub>/cm<sup>3</sup></b>	2.051
<b>μ/mm<sup>-1</sup></b>	0.228
<b>F(000)</b>	320.0
<b>Crystal size/mm<sup>3</sup></b>	0.17 × 0.07 × 0.04
<b>Radiation</b>	Mo Kα (λ = 0.71073)
<b>2θ range for data collection/°</b>	5.244 to 49.984
<b>Index ranges</b>	-6 ≤ h ≤ 6, -18 ≤ k ≤ 18, -7 ≤ l ≤ 7
<b>Reflections collected</b>	3070
<b>Independent reflections</b>	931 [R <sub>int</sub> = 0.0596, R <sub>sigma</sub> = 0.0889]
<b>Data/restraints/parameters</b>	931/0/100
<b>Goodness-of-fit on F<sup>2</sup></b>	1.031
<b>Final R indexes [I &gt;= 2σ (I)]</b>	R <sub>1</sub> = 0.0517, wR <sub>2</sub> = 0.1036
<b>Final R indexes [all data]</b>	R <sub>1</sub> = 0.0998, wR <sub>2</sub> = 0.1206
<b>CCDC deposition number</b>	2347086


### S3. Powder X-ray Data and Phase Analysis




**Figure S1.** Powder X-ray diffractograms of **(PhBE)·(azop)** simulated from single crystal data (top) and experimental (bottom).




**Figure S2.** Phase composition analysis of **(PhBE)·(azop)** using experimental and simulated from single crystal data. Phase analysis was carried out using Match! software using profile fitting.<sup>6</sup>




**Figure S3.** Powder X-ray diffractograms of **(PhBE)·(diF-azop)** simulated from single crystal data (top) and experimental (bottom).




**Figure S4.** Phase composition analysis of **(PhBE)·(diFazop)** using experimental and simulated from single crystal data. Phase analysis was carried out using Match! software using profile fitting.<sup>6</sup>




**Figure S5.** Powder X-ray diffractograms of  $(\text{PhBE}) \cdot (\text{tetraF-azop})$  simulated from single crystal data (top) and experimental (bottom).




**Figure S6.** Phase composition analysis of  $(\text{PhBE}) \cdot (\text{tetraFazop})$  using experimental and simulated from single crystal data. Phase analysis was carried out using Match! software using profile fitting.<sup>6</sup>




**Figure S7.** Powder X-ray diffractograms of **(PhBE)·(perF-azop)** simulated from single crystal data (top) and experimental (bottom).




**Figure S8.** Phase composition analysis of **(PhBE)·(perFazop)** using experimental and simulated from single crystal data. Phase analysis was carried out using Match! software using profile fitting.<sup>6</sup>




**Figure S9.** Powder X-ray diffractograms of **diF-azop** simulated from single crystal data (top) and experimental (bottom).



**Figure S10.** Phase composition analysis of **diFazop** using experimental and simulated from single crystal data. Phase analysis was carried out using Match! software using profile fitting.<sup>6</sup>




**Figure S11.** Powder X-ray diffractograms of **tetraF-azop** simulated from single crystal data (top) and experimental (bottom).




**Figure S12.** Phase composition analysis of **tetraFazop** using experimental and simulated from single crystal data. Phase analysis was carried out using Match! software using profile fitting.<sup>6</sup>





**Figure S13.** Powder X-ray diffractograms of **perF-azop** simulated from single crystal data (top) and experimental (bottom).



**Figure S14.** Phase composition analysis of **perF-azop** using experimental and simulated from single crystal data. Phase analysis was carried out using Match! software using profile fitting.<sup>6</sup>

## S4. NMR Spectra




Figure S15. <sup>1</sup>H NMR spectra of diF-azop (400 MHz, CDCl<sub>3</sub>).







Figure S16. <sup>19</sup>F NMR spectra of diF-azop (400 MHz, CDCl<sub>3</sub>).




**Figure S17.** <sup>1</sup>H NMR spectra of **tetraF-azop** (400 MHz, CDCl<sub>3</sub>).




**Figure S18.** <sup>19</sup>F NMR spectra of **tetraF-azop** (400 MHz, CDCl<sub>3</sub>).




**Figure S19.** <sup>1</sup>H NMR spectra of perF-azop (400 MHz, CDCl<sub>3</sub>).




**Figure S20.** <sup>19</sup>F NMR spectra of perF-azop (400 MHz, CDCl<sub>3</sub>).




**Figure S21.**  $^1\text{H}$  NMR spectra of  $(\text{PhBE})\cdot(\text{azop})$  (400 MHz,  $\text{DMSO-}d_6$ ). We note the adduct dissociated in solution.



**Figure S22.**  $^1\text{H}$  NMR spectra of  $(\text{PhBE})\cdot(\text{diF-azop})$  (400 MHz,  $\text{DMSO-}d_6$ ). We note the adduct dissociated in solution.




**Figure S23.**  $^1\text{H}$  NMR spectra of  $(\text{PhBE}) \cdot (\text{tetraF-azop})$  (400 MHz,  $\text{DMSO-}d_6$ ). We note the adduct dissociated in solution.




**Figure S24.**  $^1\text{H}$  NMR spectra of  $(\text{PhBE}) \cdot (\text{perF-azop})$  (400 MHz,  $\text{DMSO-}d_6$ ). We note the adduct dissociated in solution.


## S5. Hirshfeld analysis




**Figure S25.** 2D Hirshfeld projections along the *a*-axis of adducts and co-crystal: a) (PhBE)·(azop), b) (PhBE)·(diF-azop), c) (PhBE)·(tetraF-azop), and d) (PhBE)·(perF-azop).




**Figure S26.** Selected Hirshfeld projection interactions for (PhBE)·(azop) structure: a) C-C interactions, b) C-H interactions, and c) N-H interactions.



**Figure S27.** Selected Hirshfeld projection interactions for **(PhBE)·(diFazop)** structure: a) C-C interactions, b) C-H interactions, and c) N-H interactions.




**Figure S28.** Selected Hirshfeld projection interactions for **(PhBE)·(tetraF-azop)** structure: a) C-C interactions, b) C-H interactions, and c) N-H interactions.



**Figure S29.** Selected Hirshfeld projection interactions for **(PhBE)·(perF-azop)** structure: a) C-C interactions, b) C-H interactions, and c) N-H interactions.





**Table S8.** Selected projection interaction percentages of the reported cocystal structures.

## References

1. N. Iranpoor, H. Firouzabadi, D. Khalili and S. Motevalli, *J. Org. Chem.*, 2008, **73**, 4882-4887.
2. G. M. Sheldrick, *Acta Cryst. A*, 2015, **71**, 3-8.
3. G. M. Sheldrick, *Acta Cryst. C*, 2015, **71**, 3-8.
4. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. Howard and H. Puschmann, *J. Appl. Crystallogr.*, 2009, **42**, 339-341.
5. (a) J.-D. Chai and M. Head-Gordon, *Phys. Chem. Chem. Phys.*, 2008, **10**, 6615-6620; (b) Y. K. Kang and H. S. Park, *Chem. Phys. Lett.*, 2014, **600**, 112-117.
6. H. Putz and K. Brandenburg GbR, Match! - Phase Analysis using Powder Diffraction (version Version 3) Crystal Impact, Kreuzherrenstr. 102 53227 Bonn, Germany.